Rosuvastatin 20-40 mg orally daily Low intensityStatin(age >75 years, orStatinintolerant) Rosuvastatin 25-10 mg orally daily Indications to start at lower dose (5 mg) Asians Higher drug levels leads to higher toxicity risk Renal Insufficiency(max 10 mg ifCrCl< 30 ml/min) ...
In several RCTs low dose of rosuvastatin was more effective in reducing LDL-C levels compared to the other statins (simvastatin, atorvastatin and pravastatin), proving to be the most powerful agent in CV risk reduction [6⿿10]. On the other hand, cost/benefit analysis and the recent availa...
Rosuvastatin crosses the placenta in rats and rabbits and is found in fetal tissue and amniotic fluid at 3% and 20%, respectively, of the maternal plasma concentration following a single 25 mg/kg oral gavage dose on gestation day 16 in rats. In rabbits, fetal tissue distribution was 25% of...
baseline TG levels from 273 to 817 mg/dL, rosuvastatin calcium given as a single daily dose (5 to 40 mg) over 6 weeks significantly reduced serum TG levels (Table 9). Table 9: Dose-Response in Patients with Primary Hypertriglyceridemia over 6 Weeks Dosing Median (Min, Max) Percent Change...
The coadministration of rosuvastatin with metformin produced a significant pharmacokinetic interaction in rosuvastatin Css,max, with the 90% CI for the geometric mean ratio (coadministration:monoadministration) being 110.27% to 136.39% (P = 0.0029), whereas no significant interaction was observed in ...
It has a prolonged duration of action, with terminal t1/2 of ～20 h, compatible with once-daily dosing. In humans, rosuvastatin is minimally metabolized through CYP2C9 and CYP2C19, with little or no metabolism via the CYP3A4. Approximately 90% of the administered oral dose is eliminated ...
dose required (75–200 mg twice daily) Rosuvastatin Dose (mg)a 10 mg daily for 10 days Change in AUCb ↑ 7-foldc Change in Cb max ↑ 11-foldc Gemfibrozil 600 mg twice daily for 7 days Lopinavir/ritonavir combination 400 mg/100 mg twice daily for 10 days Atazanavir/ritonavir ...
one-sequence studies with multiple-dose administration for elderly (n = 20) and young (n = 32) subjects were conducted. All subjects received 20 mg of rosuvastatin once daily for 21 days. The exposure to rosuvastatin, characterized by the area under the time curve (AUC), increase...
We, then, analysed the in vitroe?ectsofrosuvavastatinonHUVECs.Theinhibition of HUVEC proliferation by rosuvastatin (10–100μM) was dose- and time-dependent (Figure8(a)). After 24 hours, rosuvastatin inhibited HUVEC proliferation by approxi- mately25%forallconcentrations.Adose-dependente?ect ...
(33.8±11.4 vs. 59.6±22.2ng.h/ml, p=0.018; 34.9±11.9 vs. 62.2±23.5ng.h/ml, p=0.018), respectively. The C(max) value was higher in the 421CA+421AA group than in the 421CC group (9.9±5.4 vs. 5.1±2.4ng/ml, p=0.048). The CL/F value was lower in the 421CA+421AA ...